$CDNA

Hanna John Walter JR sold $425K of CDNA

Hanna John Walter JR (President and CEO) sold 17,683 shares of CareDx, Inc. (CDNA) at $24.03 ($0.42M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

10b5-1 plans often lead to predictable selling schedules; without additional context (e.g., multiple consecutive sales, changes in plan size), the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-17, transaction dated 2026-06-15

Background

The article is a SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO Hanna John Walter Jr sold 17,683 shares at $24.0274 in an open-market transaction filed as a Form 4.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single CEO 10b5-1 sale.

None.

None.

Counterpoint

The sale may be purely planned liquidity, so it should not be treated as a bearish signal about CareDx fundamentals.

Key entities

  • CareDx, Inc.

    Company whose CEO insider sale is disclosed in the Form 4.

  • Hanna John Walter Jr

    President and CEO and reporting person who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

$CDNAHighAI 9/10

Why CareDx Stock Jumped Today

CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.

$CDNAHigh

CareDx, Inc. (CDNA): Results of Operations and Financial Condition

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million BRISBANE, Calif. — (BUSINESS WIRE)